Your browser is no longer supported. Please, upgrade your browser.
HTG Molecular Diagnostics, Inc.
Index- P/E- EPS (ttm)-3.17 Insider Own0.30% Shs Outstand6.69M Perf Week-1.05%
Market Cap42.17M Forward P/E- EPS next Y-2.00 Insider Trans0.00% Shs Float6.47M Perf Month-7.21%
Income-17.20M PEG- EPS next Q-0.70 Inst Own37.10% Short Float1.95% Perf Quarter-2.25%
Sales7.90M P/S5.34 EPS this Y40.60% Inst Trans- Short Ratio2.68 Perf Half Y24.12%
Book/sh2.76 P/B2.05 EPS next Y21.30% ROA-47.10% Target Price9.75 Perf Year25.61%
Cash/sh4.00 P/C1.41 EPS next 5Y- ROE-104.10% 52W Range3.50 - 7.95 Perf YTD18.16%
Dividend- P/FCF- EPS past 5Y43.10% ROI-64.50% 52W High-28.81% Beta1.48
Dividend %- Quick Ratio4.70 Sales past 5Y16.20% Gross Margin52.30% 52W Low61.71% ATR0.28
Employees83 Current Ratio5.00 Sales Q/Q5.00% Oper. Margin- RSI (14)44.40 Volatility4.02% 4.67%
OptionableNo Debt/Eq0.84 EPS Q/Q70.00% Profit Margin- Rel Volume0.29 Prev Close5.77
ShortableYes LT Debt/Eq0.64 EarningsAug 12 AMC Payout- Avg Volume47.00K Price5.66
Recom2.00 SMA20-1.78% SMA50-5.84% SMA2001.03% Volume13,835 Change-1.91%
May-11-20Resumed Cantor Fitzgerald Overweight
Mar-26-20Downgrade Craig Hallum Buy → Hold
May-16-17Reiterated Rodman & Renshaw Buy $4.50 → $6
Aug-22-16Initiated Rodman & Renshaw Buy $5
Apr-04-16Reiterated Canaccord Genuity Buy $10 → $7
Nov-24-15Reiterated Canaccord Genuity Buy $12 → $10
Aug-24-15Reiterated Canaccord Genuity Buy $17 → $12
Jun-03-15Initiated JMP Securities Mkt Outperform
Jun-02-15Initiated Leerink Partners Outperform $18
Jun-02-15Initiated Canaccord Genuity Buy $17
Oct-06-21 09:33AM  
Oct-05-21 08:00AM  
Sep-21-21 08:00AM  
Sep-08-21 04:10PM  
Aug-12-21 04:05PM  
Aug-05-21 08:00AM  
Aug-03-21 08:00AM  
Jul-23-21 08:00AM  
Jul-20-21 08:00AM  
Jun-25-21 02:41AM  
Jun-22-21 08:00AM  
Jun-21-21 05:29PM  
Jun-14-21 08:00AM  
May-24-21 04:11PM  
May-13-21 04:05PM  
May-04-21 04:01PM  
Apr-06-21 09:20AM  
Apr-05-21 04:03PM  
Mar-25-21 04:01PM  
Mar-18-21 12:30PM  
Mar-16-21 04:01PM  
Feb-26-21 08:00AM  
Jan-19-21 04:10PM  
Jan-05-21 08:00AM  
Dec-30-20 08:00AM  
Dec-18-20 08:00AM  
Dec-08-20 04:01PM  
Nov-29-20 02:23PM  
Nov-23-20 08:00AM  
Nov-15-20 08:32AM  
Nov-10-20 04:29PM  
Nov-09-20 10:20AM  
Nov-02-20 04:01PM  
Oct-30-20 08:00AM  
Oct-28-20 03:30PM  
Sep-08-20 04:01PM  
Aug-18-20 08:00AM  
Aug-14-20 02:17PM  
Aug-11-20 06:19PM  
Aug-10-20 04:01PM  
Aug-05-20 04:01PM  
Aug-04-20 08:00AM  
Jul-30-20 04:01PM  
Jul-28-20 04:05PM  
Jul-23-20 04:05PM  
Jun-25-20 04:01PM  
Jun-24-20 08:56AM  
Jun-23-20 04:01PM  
Jun-18-20 04:01PM  
Jun-11-20 04:01PM  
Jun-04-20 10:13PM  
Jun-02-20 08:00AM  
May-14-20 10:14AM  
May-13-20 05:25PM  
May-11-20 04:01PM  
May-07-20 12:30PM  
Mar-31-20 08:52AM  
Mar-27-20 09:38PM  
Mar-25-20 04:01PM  
Mar-18-20 12:30PM  
Mar-17-20 08:00AM  
Feb-27-20 12:30PM  
Feb-19-20 08:00AM  
Feb-11-20 08:00AM  
Feb-05-20 08:00AM  
Jan-28-20 08:00AM  
Jan-13-20 08:00AM  
Dec-14-19 06:39PM  
Dec-03-19 07:42PM  
Nov-19-19 08:00AM  
Nov-14-19 06:38AM  
Nov-12-19 05:55PM  
Nov-08-19 04:30PM  
Nov-05-19 10:32AM  
Oct-31-19 08:00AM  
Oct-22-19 08:00AM  
Oct-15-19 08:00AM  
Oct-10-19 08:00AM  
Sep-30-19 08:00AM  
Sep-24-19 04:05PM  
Sep-20-19 11:02AM  
Sep-19-19 04:01PM  
Aug-20-19 04:05PM  
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.